Research firm IMS Health has been collecting data on the number of prescriptions filled for certain drugs as well as the top selling drugs. The data that they collected was from July 2013 to June 2014; a full 12 months. From the lists of the top 100 drugs, I’ve narrowed it down to drugs that …
A newly released report from research firm IMS Health collected data on the most prescribed drugs in the United States from June 2013 to July 2014. Although the number one drug was Synthroid, a thyroid medication with over 22 million prescriptions, rounding out the top ten most prescribed were Cymbalta (#8), Vyvanse (#9), and Lyrica …
When it comes to depression, most people are looking for a treatment that allows them to feel happier, while minimizing potential side effects. There are many antidepressants on the market, and while some may work slightly better than others, most research indicates that the efficacy among approved drugs is very similar. If you are looking …
There is mounting preliminary evidence suggesting that Botox treatment for depression works quite well. In fact just receiving one injection of cosmetic botulinum toxin (BTX) could ward off the blues. Although only smaller studies have been conducted, most researchers believe that Botox treatments target facial muscles that are responsible for both expressing and regulating emotions. …
Testosterone is considered a steroid hormone that is secreted mostly by the testicles in men, with additional small amounts secreted by the adrenal glands. It is from the androgen group, and is a male sex hormone with anabolic properties. In men, testosterone is vital for helping develop reproductive tissues (testicles, prostate, etc.). It also promotes …
Lyrica (Pregabalin) is an anticonvulsant drug utilized primarily to treat neuropathic pain. It is also used as an adjunctive treatment option for adults with partial seizures. In countries outside of the United States, it was approved in 2007 to treat generalized anxiety disorder. Doctors also have found that it works well to treat chronic pain …
ALKS-5461 is a new drug that is being developed by the company Alkermes as an alternative to SSRI’s for the treatment of depression. ALKS-5461 (its trial name) is a combination of both buprenorphine (suboxone) and samidorphan, and is regarded as a non-addictive opioid modulator and antidepressant. It is currently being developed specifically as an antidepressant …